Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

NCT03255083 ·Status: TERMINATED ·Phase: PHASE1

Osimertinib for NSCLC With Uncommon EGFR Mutations

NCT05421936 ·Status: SUSPENDED

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

NCT04811001 ·Status: UNKNOWN ·Phase: PHASE2

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

NCT05215951 ·Status: TERMINATED ·Phase: PHASE2

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

NCT06486142 ·Status: RECRUITING ·Phase: PHASE3

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

NCT06538038 ·Status: RECRUITING

Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

NCT07279935 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097 ·Status: RECRUITING ·Phase: PHASE3

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

NCT03239340 ·Status: COMPLETED ·Phase: PHASE2

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

NCT04335292 ·Status: RECRUITING ·Phase: PHASE2

Efficacy of Osimertinib in Patients With Lung Cancer

NCT06174857 ·Status: RECRUITING

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

NCT04410796 ·Status: RECRUITING ·Phase: PHASE2

A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

NCT06530719 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.

NCT07213076 ·Status: COMPLETED

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

NCT06039683 ·Status: COMPLETED

Osimertinib In EGFR Mutant Lung Cancer

NCT03586453 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

NCT03535363 ·Status: COMPLETED ·Phase: PHASE1

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

NCT03122717 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

NCT04317651 ·Status: UNKNOWN

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Retrospective Study in a NSCLC M+ p

NCT01795352 ·Status: COMPLETED

Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma

NCT06383728 ·Status: RECRUITING ·Phase: PHASE2